ST. LOUIS & MENLO PARK, Calif.--(BUSINESS WIRE)--Covidien (NYSE:COV) (BSX:COV) and Depomed, Inc. (NASDAQ:DEPO) today announced that Covidien has licensed worldwide rights from Depomed to utilize Depomed’s AcuFormTM gastric retentive drug delivery technology for the exclusive development of four undisclosed products. The products will target a key strategic focus of Covidien’s pharmaceutical business and address major medical needs.
